Menu
Recruiting NCT06936618

EIT-Guided Ventilator Settings in AHRF

No phase Interventional Acute Hypoxemic Respiratory Failure Acute Respiratory Distress Syndrome (ARDS) Mechanical Power Ventilator Induced Lung Injury

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Electrical Impedance Tomography (EIT), Enlight 2100.
Who it may be relevant to
Registry conditions: Acute Hypoxemic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS), Mechanical Power, Ventilator Induced Lung Injury. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Thailand
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Using Electrical Impedance Tomography-Guided Ventilator Settings to Reduce Mechanical Power in Acute Hypoxemic Respiratory Failure : An Exploratory Study

Overview

This exploratory study aims to investigate the effect of Electrical Impedance Tomography (EIT)-guided ventilator settings on mechanical power in patients with acute hypoxemic respiratory failure (AHRF), including both ARDS and non-ARDS conditions. Mechanical power, a key factor associated with ventilator-induced lung injury (VILI), will be measured before and after EIT-guided PEEP titration. The study will evaluate feasibility and changes in lung mechanics, gas exchange, and EIT parameters. A total of 17 patients requiring invasive mechanical ventilation will be enrolled at Siriraj Hospital, Mahidol University.

Detailed description

This exploratory study investigates the effect of Electrical Impedance Tomography (EIT)-guided PEEP titration on mechanical power in patients with acute hypoxemic respiratory failure (AHRF), including both ARDS and non-ARDS conditions such as severe pneumonia and pulmonary edema. Mechanical power represents the energy transferred from the ventilator to the respiratory system per unit time and has been associated with the development of ventilator-induced lung injury (VILI).

Patients who meet the inclusion criteria will undergo a standardized EIT-guided PEEP titration protocol using the Enlight 2100 EIT device. Optimal PEEP is defined as the PEEP level that minimizes both alveolar overdistension and collapse based on real-time EIT measurements. Mechanical power and other ventilatory parameters (lung compliance, plateau pressure, driving pressure, 4∆P x RR index, and gas exchange) will be assessed before and after PEEP titration at predefined time points (baseline, 2, 12, and 24 hours).

The study also evaluates the regional ventilation distribution ratios, as well as safety outcomes including hemodynamic instability, arrhythmias, and pneumothorax. Patients will be followed for up to 28 days to record duration of mechanical ventilation, ICU stay, and 28-day mortality.

This study aims to assess the feasibility and physiological benefits of personalized ventilator settings using EIT in critically ill patients with AHRF and to generate preliminary data for future interventional studies.

Interventions

  • Device Electrical Impedance Tomography (EIT), Enlight 2100
    Patients will undergo ventilator adjustments using EIT-guided PEEP titration to optimize mechanical power and lung mechanics.

Primary outcome measures

  • Change in Mechanical Power [Time frame: ฺBaseline and 2 hours after EIT-guided ventilator adjustment and follow-up over 24 hours (baseline, 2 hours, 12 hours, and 24 hours after EIT-guided ventilator adjustment)]
Secondary outcome measures (12)
  • Change in PEEP level [Time frame: At baseline and then 2 hours, 12 hours, 24 hours after EIT-guided PEEP titration]
  • Change in Respiratory Static Compliance [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • Change in Driving Pressure [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • Change in Plateau Pressure [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • Change in 4∆P + RR Index [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • Change in Elastic dynamic power [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • change in elastic static power [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • Change in resistive power [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • Change in arterial oxygen tension (PaO₂) [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • Ventilation distribution ratio [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]
  • Incidence of complication [Time frame: Up to 24 hours after intervention]
  • Change in arterial carbon dioxide tension (PaCO₂) [Time frame: Baseline, 2 hours, 12 hours, and 24 hours after intervention]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosed with acute hypoxemic respiratory failure within 48 hours
  • Expected to require invasive mechanical ventilation ≥ 48 hours
  • On mechanical ventilation within 24 hours
  • Deep sedation and neuromuscular blockade

Exclusion criteria

  • Pregnancy
  • Body mass index (BMI) > 40 kg/m2
  • Contraindications to using electrical impedance tomography, including
  • Presence of a pacemaker or automatic implantable cardioverter-defibrillator (AICD)
  • Inability to place the belt due to presence of surgical wounds dressing, thoracic or spinal cord trauma, recent thoracic surgery, etc.
  • High risk for PEEP titration
  • Hemodynamic instability defined as mean arterial pressure < 65 mmHg despite optimization of fluid status and/or use of vasopressors
  • Unstable cardiac arrhythmias
  • Presence of lung bullae greater than 2 cm in diameter, identified on chest X-ray
  • Presence of pneumothorax or pneumomediastinum
  • Right-sided heart failure or severe pulmonary hypertension
  • Neurologic conditions associated with a risk of intracranial hypertension
  • Use of extracorporeal membrane oxygenation (ECMO)
  • Severe chronic respiratory disease, defined as follows: requiring home oxygen therapy, or previous lung function showing (FEV1 less than 20 ml/kg PBW, or FEV1/FVC less than 50% predicted value), or chronic hypercapnia (PaCO2 greater than 45 mmHg) and/or chronic hypoxemia (PaO2 less than 55 mmHg) on FIO2 = 0.21, or radiographic x-ray evidence of any chronic over-inflation or chronic interstitial infiltration, or chronic restrictive, obstructive, neuromuscular, chest wall or pulmonary vascular disease resulting in severe exercise restriction (unable to climb stairs or perform household duties, secondary polycythemia, severe pulmonary hypertension with mean pulmonary arterial pressure greater than 40 mmHg)
  • Decision to withhold life-sustaining treatment or palliative care.
  • Moribund status with an expected survival of less than 24 hours.
  • Refusal to provide informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Thailand · 1 center
  • Siriraj Hospital, Mahidol University — Bangkok

Identifiers

NCT: NCT06936618 · SI 962/2024

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗